CASI Pharmaceuticals (CASI) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Do analysts rate CASI or CHRS?

CASI Pharmaceuticals presently has a consensus target price of $6.00, suggesting a potential upside of 140.96%. Coherus BioSciences has a consensus target price of $5.38, suggesting a potential upside of 298.15%. Given Coherus BioSciences' higher possible upside, analysts plainly believe Coherus BioSciences is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Coherus BioSciences	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has preferable valuation and earnings, CASI or CHRS?

CASI Pharmaceuticals has higher earnings, but lower revenue than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$33.88M	1.14	-$26.94M	-$2.23	-1.12
Coherus BioSciences	$257.24M	0.60	-$237.89M	-$0.08	-16.88

Which has more volatility and risk, CASI or CHRS?

CASI Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Is CASI or CHRS more profitable?

Coherus BioSciences has a net margin of -0.15% compared to CASI Pharmaceuticals' net margin of -143.18%. Coherus BioSciences' return on equity of 0.00% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%
Coherus BioSciences	-0.15%	N/A	-24.44%

Does the media prefer CASI or CHRS?

In the previous week, Coherus BioSciences had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 3 mentions for Coherus BioSciences and 2 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 1.43 beat Coherus BioSciences' score of 0.41 indicating that CASI Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CASI Pharmaceuticals	Positive
Coherus BioSciences	Neutral

Does the MarketBeat Community favor CASI or CHRS?

Coherus BioSciences received 248 more outperform votes than CASI Pharmaceuticals when rated by MarketBeat users. Likewise, 65.31% of users gave Coherus BioSciences an outperform vote while only 50.13% of users gave CASI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
CASI Pharmaceuticals	Outperform Votes 200 50.13%	Underperform Votes 199 49.87%
Coherus BioSciences	Outperform Votes 448 65.31%	Underperform Votes 238 34.69%

Do insiders and institutionals have more ownership in CASI or CHRS?

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Coherus BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Coherus BioSciences beats CASI Pharmaceuticals on 12 of the 18 factors compared between the two stocks.